- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06426147
L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)
A Randomised, Double-blind, Placebo-controlled Trial of L-Citrulline Oral Supplementation to Improve Short and Long-term Outcomes of Admitted Febrile Paediatric Patients With Biomarker-determined High-risk of Adverse Outcomes
In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis. In fact, understanding at first encounter their risk of developing adverse outcomes (including mortality) could allow a more focused management and the tailoring of specific interventions to decrease in hospital mortality, and post discharge adverse longer-term outcomes. This clinical trial, part of the EChiLiBRiST larger project ("Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival") has the two-fold objective of:
- Assessing whether a POINT-OF-CARE rapid triaging test (PoC RTT) based on the quantitative measurement at the bedside of the "prognostic" biomarker sTREM-1 (soluble-triggering receptor expressed on myeloid cells 1) can reliably identify those admitted children with a higher risk of adverse outcomes; and
- Assessing whether the therapeutic intervention (the L-arginine precursor, L-Citrulline, key in the nitric oxide biosynthesis), administered orally for 28 days to those children aged 1-<60 months identified as "moderate-to-high risk" by the prognostic biomarker can improve outcomes as compared to those receiving an indistinguishable placebo.
This second objective will be assessed in a prospective multi-country, multi-site, individually randomised, two-arm, placebo-controlled, double blind clinical trial involving ~888 children 1-<60m of age admitted to hospital and determined to be at high risk of adverse outcomes by their baseline sTREM-1 levels. The trial will compare the efficacy of a twice-daily dose of L-citrulline syrup vs placebo (200-300mg/kg/day depending on weight-band; for 28 days) in reducing adverse outcomes in children with severe disease. The trial will be running independently but in parallel in two high-mortality settings in Mozambique and in Ethiopia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Quique Bassat, Prof
- Phone Number: 93 227 92 12
- Email: quique.bassat@isglobal.org
Study Contact Backup
- Name: Barbara Baro, PhD
- Phone Number: 93 227 92 12
- Email: Barbara.baro@isglobal.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Enrolled in the initial prognostic screening component.
- Sick children with fever (axillary temperature>37.5ºC) or a history of fever (within the preceding 72h) or with suspected severe disease.
- 1m-<60 months of age.
- With an indication for admission, or having already been admitted to hospital due to their illness.
- With an sTREM-1 PoC result classifying their disease as of "moderate-high risk" ("yellow" or "red") upon study recruitment and within D3.
- Residents in the study area or willing to be contacted and traced during the study duration.
- Willing to sign an informed consent document.
- Willing to undergo and adhere to study procedures as explained in the IC document.
Exclusion Criteria:
- Admission to hospital for social reasons (and not on account of their disease).
- Children for which informed consent document has not been signed.
- Known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet.
- Concurrent participation in any other clinical trial.
- Patient under NPO or "nothing by mouth" prescription .
- Contraindication for the insertion of a nasogastric tube (NGT) of for the enteral administration of drugs through the NGT in children who cannot tolerate by mouth.
- Critically sick patient whose prognosis is considered by the clinical researcher as fatal outcome in the following hours after screening.
- Any other condition determined by the investigators that makes it unlikely that the participant would complete the follow up until day 28 of study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L-citrulline
1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
|
1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
|
Placebo Comparator: Placebo
1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
|
1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse disease outcome
Time Frame: Up to day 28
|
Proportion of participants with "adverse disease outcome" defined as a composite of (i.e., the occurrence between D0 and D28 after recruitment of at least one -or more- of the following adverse outcomes):
|
Up to day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: Up to day 28
|
Proportion of participants with mortality between day 0 and day 28 after recruitment and/or up to hospital discharge.
|
Up to day 28
|
Incident neurological sequelae
Time Frame: Up to day 28
|
Proportion of participants with incident neurological sequelae between day 0 and day 28 after recruitment and/or up to hospital discharge.
|
Up to day 28
|
Major adverse kidney event
Time Frame: Up to day 28
|
Proportion of participants with major adverse kidney event at discharge (MAKE-DC, defined as a severe AKI event between 2-7 days or a discharge eGFR<60mL/min per 1.73m2)
|
Up to day 28
|
Need for organ support
Time Frame: Up to day 28
|
Proportion of participants with need for organ support
|
Up to day 28
|
Clinical shock
Time Frame: Up to day 28
|
Proportion of participants with clinical shock
|
Up to day 28
|
Severe respiratory distress
Time Frame: Up to day 28
|
Proportion of participants with severe respiratory distress
|
Up to day 28
|
Coma
Time Frame: Up to day 28
|
Proportion of participants with coma
|
Up to day 28
|
Need for readmission
Time Frame: Up to day 28
|
Proportion of participants with need for readmission within the first 28 days post-recruitment (after having been discharged)
|
Up to day 28
|
Median duration of antibiotic treatment
Time Frame: Up to day 28
|
Median duration of antibiotic treatment up to day 28
|
Up to day 28
|
Oxygen requirement
Time Frame: Up to day 28
|
Proportion of participants with oxygen requirement up to D28 and/or up to hospital discharge
|
Up to day 28
|
Radiological pneumonia
Time Frame: Up to day 28
|
Proportion of participants with radiological pneumonia among children with RTI up to D28 and/or up to hospital discharge
|
Up to day 28
|
Hypoxemia (Sp02 <90%)
Time Frame: Up to day 28
|
Proportion of participants with hypoxemia (Sat 02<90% irrespective of supplementary oxygen in absence of cyanotic heart disease) up to D28 and/or up to hospital discharge
|
Up to day 28
|
Lenght of hospitalisation
Time Frame: Up to day 28
|
Length of hospitalisation up to D28 and/or up to hospital discharge
|
Up to day 28
|
Mortality
Time Frame: Up to month 6
|
Proportion of participants with mortality up to M6
|
Up to month 6
|
Secondary consultation or hospitalisations
Time Frame: Up to month 6
|
Proportion of participants with secondary consultations or hospitalisations up to M6
|
Up to month 6
|
Proportion of participants with serious adverse events
Time Frame: Up to month 6
|
Proportion of participants with serious adverse events up to month 6
|
Up to month 6
|
Proportion of participants with suspected unexpected serious adverse reactions
Time Frame: Up to month 6
|
Proportion of participants with suspected unexpected serious adverse reactions up to M6.
|
Up to month 6
|
Proportion of participants with adverse events
Time Frame: Up to day 30
|
Proportion of participants with adverse events up to D30.
|
Up to day 30
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of circulating mediators of host immune and endothelial function, inflammation, intestinal barrier function, and neuronal damage
Time Frame: Up to day 7
|
Concentration of circulating mediators of host immune and endothelial function, inflammation, intestinal barrier function, and neuronal damage at baseline, D3 and D7
|
Up to day 7
|
Lactate levels
Time Frame: Up to day 3
|
Levels of lactate at baseline and D3
|
Up to day 3
|
Levels of markers of kidney function
Time Frame: Up to day 7
|
Levels of markers of kidney function (creatinine, urea, saliva urea nitrogen (SUN), uNGAL etc.) at baseline, D3, D7 and at discharge
|
Up to day 7
|
PoC-RTT prognostic performance
Time Frame: Up to day 28
|
Prognostic performance of PoC-RTT measured sTREM-1 values at baseline among children (0-<60 months of age) with adverse outcomes up to D28.
|
Up to day 28
|
Prognostic performance of a larger panel of biomarkers
Time Frame: At baseline
|
Prognostic performance of a larger panel of prognostic biomarkers (circulating markers of endothelial function, inflammation, intestinal barrier function, and neuronal damage) at baseline.
|
At baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Quique Bassat, Prof, Barcelona Institute for Global Health
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EChiLiBRiST CT2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This clinical trial, as part of the wider EChiLiBRiST project, is committed to EU-funded Horizon 2021 aims to improve and maximize access to and reuse of research data generated by the Project.
Biological samples and data will be shared using material and data transfer agreements with the collaborating institutions.
The full protocol will be available on request to any interested professional and may be published in peer-reviewed journals or deposited in an online repository. A fully de-identified data set of the complete patient-level data will be available for sharing purposes as soon as the the analysis is completed and no later than five years after the publication of the trial.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
University of PittsburghWithdrawn
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
Clinical Trials on L-citrulline
-
Asklepion Pharmaceuticals, LLCVanderbilt UniversityCompletedHypertension, Pulmonary | Heart Defects, CongenitalUnited States
-
University of PittsburghCompleted
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
Florida State UniversityCompletedHypertensionUnited States
-
University of JordanUnknownType 2 Diabetes MellitusJordan
-
Florida State UniversityCompleted
-
University of Colorado, DenverCompleted
-
Juliano CasonattoUnknown
-
European University CyprusCompleted